SEC Form 4 · accession 0001209191-17-050294
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mary Newman
Officer — SVP, Regulatory Affairs
Period of report
Aug 24, 2017
Accepted (ET)
Aug 25, 2017 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 24, 2017 | M | 10,000 | $2.19 | A | 10,000 | D | |
| Common Stock | Aug 24, 2017 | S | 10,000 | $20.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.19 | Aug 24, 2017 | M | 10,000 | D | — | Feb 4, 2025 | Common Stock | 10,000 | 43,817 | D |
Explanation of responses
- F1This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F2The option vested as to 25% of the total shares on October 1, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on October 1, 2018, subject to the reporting person's provision of service to the issuer on each vesting date.